A New Idea of Astragaloside-Induced Bone Marrow Mesenchymal Stem Cells in the Treatment of Parkinson’s Disease

doi:10.3969/j.issn.2095-1396.2017.05.007

Abstract

Abstract:

Parkinson’s disease （PD） is a kind of neurodegenerative diseases of the central nervous system in which substantia nigra neurons are damaged and necrotic. At present，PD is mainly treated with drugs which affect the key molecular in the pathogenesis of PD or signaling pathway to alleviate the disease，however，denatured neuron could not be completely repaired. In recent years，cell therapy technology has gradually infiltrated into clinical trials and became a social focus. Bone marrow mesenchymal stem cells（BMSCs），a kind of adult pluripotent stem cells，have self-proliferation and multi-directional differentiation capabilities and are applied to explore more effective strategies for PD treatment. Astragaloside IV，a characteristic component of traditional Chinese medicine Astragalus，possesses anti-inflammatory，anti-oxidative and antiapoptotic activities. What’s more，Astragaloside IV has a protective effect on neural stem cells，and the study demonstrated that Astragaloside IV plays a neuroprotective role in PD model. This article reviewed the research progress of BMSCs and Astragaloside IV in the treatment of PD. A new idea that Astragaloside IV induced BMSCs to treat PD is proposed based on above of conclusions.

Key words: Parkinson’s disease, bone marrow mesenchymal cells, astragaloside, treatment strategy

CLC Number:

R964

Cite this article

GAO Zhi-hong1，ZUO Ya-qi2，ZHANG Xiao-li1. A New Idea of Astragaloside-Induced Bone Marrow Mesenchymal Stem Cells in the Treatment of Parkinson’s Disease[J]. Acta Neuropharmacologica, DOI: 10.3969/j.issn.2095-1396.2017.05.007.

share this article

0
/ Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: http://actanp.hebeinu.edu.cn/EN/10.3969/j.issn.2095-1396.2017.05.007

http://actanp.hebeinu.edu.cn/EN/Y2017/V7/I5/39

References

[1]李鹏涛, 高志红, 段晓亮, 等. 黄芪甲苷Ⅳ诱导SAMR1小鼠骨髓间充质干细胞分化为神经细胞的实验研究[J].河北医科大学学报, 2018, 39(11): 1338-1343.

[2]Charusheila Ramkumar，Rachel M Gerstein，Zhang Hong．Serial transplantation of bone marrow to test self-renewal capacity of hematopoietic stem cells in vivo[J].Methods Mol Biol, 2013, 976: 17-24.

[3]Chia-Wen Tsai, Rong-Tzong Tsai, Shih-Ping Liu, et al. Neuroprotective effects of betulin in pharmacological and transgenic caenorhabditis elegans models of Parkinson's disease[J].Cell Transplant, 2017, 26(12): 1903-1918.

[4]Bridget Martinez, Philip V Peplow. MicroRNAs in Parkinson's disease and emerging therapeutic targets[J].Neural Regen Res, 2017, 12(12): 1945-1959.

[5]Ruth L O'Gorman Tuura, Christian R Baumann, Heide Baumann-Vogel. Beyond dopamine: GABA, glutamate,and the axial symptoms of Parkinson disease[J].Front Neurol, 2018, 9: 806-810.

[6]Ren Shuang, Zhang Hua, Mu Yong-ping, et al. Pharmacological effects of Astragaloside IV: a literature review[J].J Tradit Chin Med, 2013, 33(3): 413-416.

[7]Luo Yu-min, Qin Zhen, Hong Zhen, et al. Astragaloside IV protects against ischemic brain injury in a murine model of transient focal ischemia[J]. Neurosci Lett, 2004, 363(3): 218-223.

[8]Gu Da-min, Lu Pei-hua, Zhang Ke, et al. EGFR mediates astragaloside IV-induced Nrf2 activation to protect cortical neurons against in vitro ischemia/reperfusion damages[J].Biochem Biophys Res Commun, 2015, 457(3): 391-397.

[9]刘浩, 张念平, 赵燕, 等.帕金森病发病机制的研究进展[J].中华老年心脑血管病杂志, 2015, 17(11): 1230-1238.

[10]Zhao Yong-fei, Zhang Qiong, Zhang Jian-feng, et al. The synergy of aging and lps exposure in a mouse model of Parkinson's disease[J].Aging Dis, 2018, 9(5): 785-797.

[11]Noemie Cresto, Camille Gardier, Francesco Gubinelli, et al. The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease[J].Eur J Neurosci.2018,30(2):6322-7403.

[12]Yaichiro Kotake. Neurotoxicity mechanism of environmental chemicals and its evaluation system[J].Yakugaku Zasshi, 2018, 138(10): 1227-1233.

[13]Yaroslau Compta, Laura Parkkinen, Sean S O'Sullivan, et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important[J].Brain, 2011, 134(5): 1493-1505.

[14]Mantri S, Fullard M, Gray S L, et al. Patterns of dementia treatment and frank prescribing errors in older adults with Parkinson disease[J].JAMA Neurol, 2018, 10(10): 20-28.

[15]Wang Ling-ling,He Chong, Liu Yue-guang, et al. Effect of acupuncture on the auditory evoked brain stem potential in Parkinson's disease[J].J Tradit Chin Med, 2002, 22(1): 15-17.

[16]徐鹏恒, 温满清, 徐伟红, 等.针灸治疗帕金森病研究进展[J].上海针灸杂志, 2018, 37(11): 1327-1330.

[17]Michael Valenzuela, Kuldip Sidhu, Sophia Dean, et al. Neural stem cell therapy for neuropsychiatric disorders[J].ActaNeuropsychiatr, 2007, 19(1): 11-26.

[18]Floriana Volpicelli, Claudia Consales, Massimiliano Caiazzo, et al. Enhancement of dopaminergic differentiation in proliferatingmidbrain neuroblasts by sonic hedgehog and ascorbic acid[J].Neural Plast, 2004, 11(1-2): 45-57.

[19]Li Li, Song Hai-jing, Mu Pei-pei, et al. The actin cytoskeleton is involved in glial cell line-derived neurotrophic factor (GDNF)-induced ret translocation into lipid rafts in dopaminergic neuronal cells[J].Int J Mol Sci, 2017, 18(9):142-150.

[20]Yu Zhong-yuan, Yang Ling, Yang Yang, et al. Epothilone B benefits nigral dopaminergic neurons by attenuating microglia activation in the 6-Hydroxydopamine lesion mouse model of Parkinson's disease[J].Front Cell Neurosci.2018,12:324-335.

[21]常学辉, 张良芝, 黎民. 龟羚帕安丸对帕金森病大鼠神经干细胞移植后中脑黑质TH、GDNF、Ptx3表达的影响[J].中成药, 2018, 40(08): 1681-1686.

[22]Yan Sun-xing, Li Pan-long, Wang Yong, et al. Nestin regulates neural stem cell migration via controlling the cell contractility[J].Int J Biochem Cell Biol, 2016, 78: 349-360.

[23]刘振华, 王世军. 帕金森病模型大鼠损毁侧纹状体内移植神经干细胞的增殖与分化[J].中国组织工程研究, 2015, 19(36): 5843-5847.

[24]Hyung-Jun Im, Do Won Hwang, Han Kyu Lee, et al. In vivo visualization and monitoring of viable neural stem cells using noninvasive bioluminescence imaging in the 6-hydroxydopamine-induced mouse model of Parkinson disease[J].Mol Imaging, 2013, 12(4): 224-234.

[25]Yang Ming, Natalie D Stull, Mathew A Berk, et al. Neural stem cells spontaneously express dopaminergic traits after transplantation into the intact or 6-hydroxydopamine-lesioned rat[J].Exp Neurol, 2002, 177(1): 50-60.

[26]Huang Xiao-ping, Qiu Yong-yuan, Wang Bei, et al. Effects of Astragaloside IV combined with the active components of Panax notoginseng on oxidative stress injury and nuclear factor-erythroid 2-related factor 2/heme oxygenase-1 signaling pathway after cerebral ischemia-reperfusion in mice[J].Pharmacogn Mag, 2014, 10(40): 402-409.

[27]何威, 杨旭辉, 林秋雄, 等.人参皂甙Rg1对体外微环境诱导人骨髓间充质干细胞成血管内皮样细胞分化的影响[J].中国中西医结合杂志, 2010, 30(11): 1201-1205.

[28]Li Min, Li Hong-yan, Fang Fang, et al. Astragaloside IV attenuates cognitive impairments induced by transient cerebral ischemia and reperfusion in mice via anti-inflammatory mechanisms[J].Neurosci Lett, 2017, 639: 114-119.

[29]Hao M, Liu Y, Chen P, et al. Astragaloside IV protects RGC-5 cells against oxidative stress[J].Neural Regen Res, 2018, 13(6): 1081-1086.

[30]Li Hong-li, Wang Ping, Huang Fei, et al. Astragaloside IV protects blood-brain barrier integrity from LPS-induced disruption via activating Nrf2 antioxidant signaling pathway in mice[J].Toxicol Appl Pharmacol, 2018, 340: 58-66.

[31]Wang Hui-Lin, Zhou Qi-Hui, Xu Meng-Bei, et al. Astragaloside IV for Experimental Focal Cerebral Ischemia: Preclinical Evidence and Possible Mechanisms[J].Oxid Med Cell Longev, 2017(1): 842-854.

[32]Sooyong Kim, II-Hwan Kang, Jung-Bum Nam, et al. Ameliorating the effect of astragaloside IV on learning and memory deficit after chronic cerebral hypoperfusion in rats[J].Molecules.2015,20(2):1904-1921.

[33]Xia Lei, Guo Dian-xuan, Chen Bing. Neuroprotective effects of astragaloside IV on Parkinson disease models of mice and primary astrocytes[J].Exp Ther Med, 2017, 14(6): 5569-5575.

[34]Maria E Solesio, Tracy A Prime, Logan Angela, et al. The mitochondria-targeted anti-oxidant MitoQ reduces aspectsof mitochondrial fission in the 6-OHDA cell model of Parkinson's disease[J].Biochim Biophys Acta, 2013, 1832(1):174-182.

[35]Liu Xiang, Zhang Jun, Wang Shi-bo, et al. Astragaloside IV attenuates the H₂O₂-induced apoptosis of neuronal cells by inhibiting α-synuclein expression via the p38 MAPK pathway[J].Int J Mol Med, 2017, 40(6):1772-1780.

[36]Zhang Zhi-Guo, Wu Lin, Wang Ju-Lei, et al. Astragaloside IV prevents MPP?-induced SH-SY5Y cell death via the inhibition of Bax-mediated pathways and ROS production[J].Mol Cell Biochem, 2012, 364(12): 209-216.

[37]Si Yin-Chu, Li Qiang, Xie Chun-E, et al. Chinese herbs and their active ingredients for activating xue (blood) promote the proliferation and differentiation of neural stem cells and mesenchymal stem cells[J].Chin Med, 2014, 9(1):13-16.

[38]Hu Hai-Yan, Yang Ren-Song, Jin Guo-Qin, et al. Effect of Astragaloside IV on Neural Stem Cell Transplantation in Alzheimer's Disease Rat Models[J].Evid Based Complement Alternat Med, 2016, 16(5):310-318.

[39]Yu Wei, Lv Zai-gang, Zhang Li-gong, et al. Astragaloside IV reduces the hypoxia-induced injury in PC-12 cells by inhibiting expression of miR-124[J].Biomed Pharmacother, 2018, 106: 419-425.

[40] Laura J A Hardwick, Fahad R Ali, Roberta Azzarelli, et al. Cell cycle regulation of proliferation versus differentiation in the central nervous system[J].Cell Tissue Res, 2015, 359(1): 187-200.

[41]Gao Han, Dou Lian-rong, Shan Liang, et al. Proliferation and committed differentiation into dopamine neurons of neural stem cells induced by the active ingredients of radix astragali[J].Neuroreport, 2018, 29(7):577-582.

[42]Liu Yue, Chong Li, Li Xiao-qing, et al. Astragaloside IV rescues MPP⁺-induced mitochondrial dysfunction through upregulation of methionine sulfoxide reductase A[J].Exp Ther Med, 2017, 14(3): 2650-2656.

Metrics

Viewed

Full text

Abstract

Abstract
References
Related Articles
Recommended Articles
Metrics

TOP